Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 17/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012321 | 0.95 | HTR4 (0.51) | HTR4F10HTR2AHTR7KCNH2 | |
| SCHEMBL12572553 | 0.90 | HTR4 (0.57) | HTR4F10HTR2AHTR7KCNH2 | |
| SCHEMBL2007760 | 0.89 | HTR4 (0.48) | HTR4F10HTR2AHTR7KCNH2 | |
| SCHEMBL2006462 | 0.89 | HTR4 (0.54) | HTR4F10HTR2AHTR7KCNH2 | |
| Hydrochloric Acid SCHEMBL2009356 | 0.88 | HTR4 (0.53) | HTR4F10HTR2AHTR7KCNH2 | |
| SCHEMBL2007530 | 0.88 | KDM4E (0.54) | HTR4F10 | |
| SCHEMBL2008627 | 0.87 | HTR4 (0.74) | HTR4 | |
| SCHEMBL8287322 | 0.86 | HTR4 (0.53) | HTR4F10HTR2AHTR7KCNH2 | |
| Hydrochloric Acid SCHEMBL2006214 | 0.86 | HTR4 (0.72) | HTR4 | |
| SCHEMBL12630140 | 0.85 | HTR4 (0.52) | HTR4HTR2AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | HTR4 1/4885F10 1912/4885HTR2A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.